Better Therapeutics

Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research

Retrieved on: 
Wednesday, February 16, 2022
Technology, Research, Medical Devices, Diabetes, Clinical Trials, Cardiology, Software, Health, Science, NASDAQ, Health, Advisory Committee on Immunization Practices, Behavior, Patient, Clinical research, MPH, Cognitive behavioral therapy, Risk, CPC, Metabolic pathway, Brain, Forward-looking statement, Circulatory system, Health education, Therapy, Metabolism, PDT Standard, Cardiovascular disease, Insurance, FDA, Degenerative disease, Partnership, Type 2 diabetes, Diabetes, Reproductive health, Faculty, Physician, PDT, Private Securities Litigation Reform Act, Research, University, Reproduction, App Store (iOS/iPadOS), Pharmaceutical industry, MD, Colorado Prevention Center (CPC) Clinical Research, Better Therapeutics, COLORADO PREVENTION CENTER (CPC) CLINICAL RESEARCH, BETTER THERAPEUTICS

The open-label, randomized, controlled study is actively recruiting patients with type 2 diabetes from the University of Colorado Health System.

Key Points: 
  • The open-label, randomized, controlled study is actively recruiting patients with type 2 diabetes from the University of Colorado Health System.
  • Todays announcement marks the second real-world study collaborator initiating enrollment within the last six months and an important milestone for Better Therapeutics, said Mark Berman, MD, chief medical officer of Better Therapeutics.
  • Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases.
  • Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

Mass General Brigham Joins Better Therapeutics in Real World Evidence Study Collaboration

Retrieved on: 
Tuesday, November 2, 2021
Mental Health, Health, Diabetes, Technology, Software, Pharmaceutical, Biotechnology, Mass General Brigham, Better Therapeutics, MASS GENERAL BRIGHAM, BETTER THERAPEUTICS

Mass General Brigham will conduct an open-label, randomized, controlled study of approximately 750 patients with type 2 diabetes, extending Better Therapeutics ongoing effort to demonstrate real world effectiveness of the use of BT-001.

Key Points: 
  • Mass General Brigham will conduct an open-label, randomized, controlled study of approximately 750 patients with type 2 diabetes, extending Better Therapeutics ongoing effort to demonstrate real world effectiveness of the use of BT-001.
  • We are excited to participate in the evaluation of BT-001 in a real world setting of participants enrolled in our remote health care program.
  • The Better Therapeutics platform blends clinical, behavioral, and psychological inputs into a series of therapy lessons and skill-building modules.
  • Mass General Brigham is a non-profit organization that is committed to patient care, research, teaching, and service to the community.

Better Therapeutics Enrolls First Patient in Real-World Evidence Study with Catalyst Health Network Evaluating BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes

Retrieved on: 
Tuesday, October 19, 2021
Biotechnology, Technology, Professional Services, Diabetes, Health, Pharmaceutical, Research, Software, Insurance, Science, Clinical Trials, Proxy, Metabolic pathway, Security (finance), Special, Behavior, File, Annual report, Patient, Ownership, PDT, Diet, Risk, Form, COVID-19, Person, Ridge, Achievement, Mergers and acquisitions, URAC, Business architecture, Hypertension, Endocrine Society, NAFLD, SEC, Name, Patent, Type 2 diabetes, Better, Cognitive behavioral therapy, Journal, U.S. Securities and Exchange Commission, Hyperlipidemia, Disease, Sale, App Store (iOS/iPadOS), FDA, Therapy, Brain, Health, Degenerative disease, Private Securities Litigation Reform Act, Forward-looking statement, Catalysis, Prospectus, EBITDA, Diabetes, Research, Form 10-K, Securities Act of 1933, Physician, Marketing, Company, Non-alcoholic fatty liver disease, Pharmaceutical industry, BT-001, Catalyst Health Network, Better Therapeutics, BT-001, CATALYST HEALTH NETWORK, BETTER THERAPEUTICS

The open-label study of patients with type 2 diabetes is actively recruiting from Catalysts primary care ecosystem to evaluate real world effectiveness of BT-001.

Key Points: 
  • The open-label study of patients with type 2 diabetes is actively recruiting from Catalysts primary care ecosystem to evaluate real world effectiveness of BT-001.
  • The Better Therapeutics platform blends clinical, behavioral, and psychological inputs into a series of therapy lessons and skill-building modules.
  • BT-001 is Better Therapeutics lead product candidate among their pipeline of FDA-regulated, prescription digital therapeutics designed to treat the underlying causes of a range of cardiometabolic conditions.
  • Catalyst Health Network enables primary care to be the difference-maker in patients lives that it was always meant to be.

Better Therapeutics to Participate in Lake Street’s 5th Annual Best Ideas Growth (BIG5) Conference on September 14-15, 2021

Retrieved on: 
Friday, September 10, 2021
Software, Research, General Health, Data Management, Technology, Public Relations, Investor Relations, Science, Communications, FDA, Other Science, Health, Diabetes, the BIG Conference, Lake Street, Better Therapeutics, Mountain Crest Acquisition Corp. II, THE BIG CONFERENCE, LAKE STREET, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the Lake Streets 5th Annual Best Ideas Growth (BIG5) Conference , which is being held virtually on September 14-15, 2021.

Key Points: 
  • Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the Lake Streets 5th Annual Best Ideas Growth (BIG5) Conference , which is being held virtually on September 14-15, 2021.
  • Lake Street will host its fifth annual BIG (Best Ideas Growth) institutional investor conference showcasing many interesting, dynamic public growth companies.
  • Our research enables institutional investors to understand emerging secular trends and identify innovative companies best positioned to benefit.
  • Lake Street provides access to capital, mergers and acquisitions advice, and strategic counsel with a focus on building relationships to unlock value and growth.

Better Therapeutics Highlights Recent Progress and Updates Outlook Through 2022

Retrieved on: 
Thursday, September 9, 2021
Mental Health, Technology, Medical Devices, FDA, Diabetes, Fitness & Nutrition, Clinical Trials, Cardiology, Software, Health, Better Therapeutics, Mountain Crest Acquisition Corp. II, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today provided an update on recent progress since announcing its intention to merge with Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) (Mountain Crest II).

Key Points: 
  • Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today provided an update on recent progress since announcing its intention to merge with Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) (Mountain Crest II).
  • Following FDA marketing authorization or clearance, it is anticipated that primary care providers will prescribe, and insurers will reimburse, Better Therapeutics PDTs much like they would a traditional medication.
  • Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address root causes of cardiometabolic diseases.
  • Better Therapeutics PDTs are intended to be prescribed by physicians and reimbursed like traditional medicines.

Better Therapeutics Secures $50 Million Debt Facility From Hercules Capital

Retrieved on: 
Wednesday, August 25, 2021
Research, Medical Devices, FDA, Public Relations, Investor Relations, Diabetes, Communications, General Health, Health, Science, Other Science, Industry, Hercules, Company, Behavior, App Store (iOS/iPadOS), Degenerative disease, Better, Heel, PDT, Annual report, Therapy, Proxy, MCAD, U.S. Securities and Exchange Commission, Technology, Form, Ownership, Metabolic pathway, Acquisition, SEC, Physician, Research, Nasdaq, Private Securities Litigation Reform Act, Disease, Health, Name, Marketing, Forward-looking statement, NYSE, Cognitive behavioral therapy, Learning, File, Achievement, Securities Act of 1933, Prospectus, Risk, PIPE, SPAC, Sale, Mergers and acquisitions, FDA, Type 2 diabetes, Brain, COVID-19, EBITDA, Security (finance), Form 10-K, Pharmaceutical industry, Dam, Risk management, Hercules Capital, Inc., Better Therapeutics, Mountain Crest Acquisition Corp. II, HERCULES CAPITAL, INC., BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it has secured a loan facility for up to $50 million from Hercules Capital, Inc. (NYSE: HTGC).

Key Points: 
  • Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it has secured a loan facility for up to $50 million from Hercules Capital, Inc. (NYSE: HTGC).
  • We are pleased to have the support and confidence of a leading lender like Hercules, said Mark Heinen, interim chief financial officer of Better Therapeutics.
  • Following marketing authorization, it is anticipated that primary care providers will prescribe and insurers will reimburse Better Therapeutics PDTs much like they would a traditional medication.
  • Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases.

Better Therapeutics Expands Real-World Evidence Study Initiative With Addition of Catalyst Health Network

Retrieved on: 
Tuesday, August 24, 2021
Health, Diabetes, Fitness & Nutrition, General Health, Clinical Trials, Pharmaceutical, Cardiology, Behavior, Degenerative disease, PDT, Blood pressure, Proxy, SEC, Research, Health, Endocrine Society, Diet, Securities Act of 1933, Achievement, Risk, Partnership, A1C, Form 10-K, Better, Therapy, U.S. Securities and Exchange Commission, Colorado, Pharmacist, Forward-looking statement, File, Prospectus, Sale, Brain, MD, App Store (iOS/iPadOS), Quality of life, MCAD, Form, Metabolic pathway, Catalysis, Nasdaq, Name, FDA, Type 2 diabetes, URAC, EBITDA, Security (finance), Company, Journal, Annual report, Ownership, Acquisition, Physician, Private Securities Litigation Reform Act, Marketing, Cognitive behavioral therapy, Patient, COVID-19, Pharmaceutical industry, Risk management, Catalyst Health Network, Better Therapeutics, CATALYST HEALTH NETWORK, BETTER THERAPEUTICS

We are looking forward to working with the team at Catalyst Health Network to lead the evaluation of BT-001 in their clinically integrated, community based primary care setting.

Key Points: 
  • We are looking forward to working with the team at Catalyst Health Network to lead the evaluation of BT-001 in their clinically integrated, community based primary care setting.
  • Catalyst is excited to partner with Better Therapeutics on this study of BT-001.
  • The Better Therapeutics platform blends clinical, behavioral, and psychological inputs into a series of therapy lessons and skill-building modules.
  • Catalyst Health Network enables primary care to be the difference-maker in patients lives that it was always meant to be.

Better Therapeutics, Inc. to Present at the Canaccord Genuity’s 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Mental Health, Mobile, Wireless, Technology, Diabetes, Cardiology, Software, Other Health, Biotechnology, General Health, Health, Health sciences, Medicine, Articles, Health informatics, Behavior modification, Digital therapeutics, Addiction, Addiction medicine, Genuity, Therapy, Cognitive behavioral therapy, Disease, Better Therapeutics, Mountain Crest Acquisition Corp. II, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.

Key Points: 
  • Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.
  • The cognitive behavioral therapy delivered by Better Therapeutics PDTs enables changes in neural pathways of the brain so lasting changes in behavior become possible.
  • Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs.
  • Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

Better Therapeutics and Colorado Prevention Center Clinical Research Launch Real-World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes

Retrieved on: 
Thursday, July 29, 2021
Software, Pharmaceutical, Health, Diabetes, Data management, Technology, Clinical trials, Mobile, Wireless, Behavior modification, Digital therapeutics, Colorado Prevention Center (CPC) Clinical Research, Better Therapeutics, Mountain Crest Acquisition Corp. II, COLORADO PREVENTION CENTER (CPC) CLINICAL RESEARCH, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

BT-001 is an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.

Key Points: 
  • BT-001 is an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.
  • The open-label, randomized, controlled study will evaluate approximately 500 patients with type 2 diabetes in the University of Colorado (UC) Health System using BT-001.
  • At Better Therapeutics, we believe the system of care desperately needs therapeutics that address the root causes of disease, said Mark Berman, MD, Chief Medical Officer of Better Therapeutics.
  • BT-001 is Better Therapeutics lead product candidate among their pipeline of FDA-regulated, prescription digital therapeutics designed to treat the underlying cause of a range of cardiometabolic conditions.

Better Therapeutics to Participate in Cowen 6th Annual FutureHealth Conference

Retrieved on: 
Monday, June 14, 2021
Technology, Mental health, Mobile, Wireless, Medical devices, Cardiology, Software, Other Health, Health, General Health, Health sciences, Health, Medical specialties, Behavior modification, Digital therapeutics, Cognitive behavioral therapy, Therapy, Behaviour therapy, Better Therapeutics, Mountain Crest Acquisition Corp. II, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is scheduled to participate in two virtual panel discussions at the Cowen 6th Annual FutureHealth Conference on June 17, 2021.

Key Points: 
  • Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is scheduled to participate in two virtual panel discussions at the Cowen 6th Annual FutureHealth Conference on June 17, 2021.
  • Better Therapeutics Head of Behavioral Medicine, Prapti Mehta, M.D., to participate in session titled Cognitive Behavioral Therapy (CBT) & Its Use In Digital Therapeutics at 10:55 a.m.
  • Better Therapeutics Co-founder and Chief Executive Officer, Kevin Appelbaum, to participate in session titled Commercialization Of Digital Therapeutics at 1:40 p.m.
  • Better Therapeutics is a prescription digital therapeutics (PDT) company delivering a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases.